Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose–response study of neostigmine for reversal of mild residual neuromuscular block induced by atracurium
2009-018214-19Phase 4Active
- Sponsor
- CHRU Nancy
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of neostigmine in None, sponsored by CHRU Nancy. Primary endpoints: Neuromuscular recovery at 5 minutes and Neuromuscular recovery at 10 minutes. Started Feb 2010; status: active.
02
Drugs
neostigmine
Beyond the preview
Go deeper on 2009-018214-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018214-19.